Encore Medical, L.P.

Encore Medical, L.P. Surgical Implant Division, doing business as Empi Inc., manufactures and delivers orthopedic surgical implants and prosthetic devices to the Department of Veterans Affairs as a large-business prime contractor (100% of recent awards), competing full-and-open with no set-aside designations. The Austin, Texas–based subsidiary of Colfax Corporation has held a federal contracting footprint since 2001 and operates across multiple product categories spanning surgical appliance manufacturing (NAICS 339113) and medical instrument supplies (PSC 6520-11).

Encore Medical's customer concentration is nearly absolute within VA. The top five customer VISNs and headquarters account for 72% of awards by count but only 49% by potential value; the divergence reflects a critical structural fact: VA Headquarters anchors the portfolio with five awards totaling $44.5 million in combined potential value, while individual VISN task orders average substantially lower dollars. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 leads by award volume at 255 awards ($2.4 million combined potential value), followed by VISN 10 with 115 awards ($1.7 million). Department of the Army Medical Command represents the sole non-VA customer in the top five by dollar value, with 17 awards worth $859 thousand.

Encore Medical's primary revenue vehicle is a single-award Indefinite Delivery Contract titled "Surgical Implant Next Generation" (IDIQ VA797P0264) awarded by VA Headquarters on September 30, 2023, with a $11.7 million ceiling through September 29, 2026 and administrative oversight in Austin, Texas with subordinate performance across VISNs 1, 2, 10, 16, 17, 19, 21, 22, and 23 nationwide. This IDC enables task orders for shoulder, hip, and knee arthroplasty products, total shoulder replacements, reverse shoulder arthroplasty, and specialized prosthetic devices. Against this vehicle, 123 task orders have been issued with a combined $811 thousand in potential value. A second vehicle, the VA Prosthetic Implants and Appliances 2016-2021 master IDIQ, has generated 240 task orders totaling $3.2 million in combined potential value. Encore Medical also holds a Blanket Purchase Agreement with VISN 16 for regional implant procurement.

Recent representative work spans individual task orders and purchase orders issued by regional VISNs. A $16.7 million firm-fixed-price shoulder implant delivery order was issued by VISN 10 in April 2026 under the master IDC. Multiple orders in the $10,000–$15,000 range for shoulder implants, hip and knee arthroplasties, reverse shoulder arthroplasty devices, and post-operative surgical supplies have been placed by VISN 10 and VISN 8 throughout 2024 and 2025. A specialized $1.7 million firm-fixed-price purchase order for Percutaneous Osseointegrated Prosthesis (POP) devices, including femoral stems, surgical instrumentation, and ancillary supplies, was awarded by VISN 22 in May 2024 to support a VA Cooperative Studies Program clinical trial. A $60 thousand shoulder prosthesis and instrumentation order was placed by the U.S. Army Medical Command (Madigan Army Medical Center, Tacoma, Washington) on a sole-source basis in August 2021.

Award velocity shows strong growth through 2024 — four awards in 2022, twenty-five in 2023, twenty-seven in 2024 — followed by a decline to sixteen in 2025 and three awards to date in 2026, suggesting the portfolio is normalizing after earlier growth. Only four awards carrying a combined potential value of $106 thousand reach ultimate completion inside the next twenty-four months, presenting minimal recompete exposure in the near term; the master IDC itself does not complete until September 2026. Encore Medical operates exclusively as a prime contractor with no subcontract footprint in the source data. The vendor's capability portfolio centers on manufacture and supply of orthopedic implants — shoulder, hip, knee components, reverse arthroplasty systems, prosthetic devices, and post-operative surgical supplies — all procured on firm-fixed-price terms with no competitive set-asides, reflecting its position as an established, preferred supplier to the VA healthcare system.